US Patent

US10117867 — Methods and compositions for sleep disorders and other disorders

Method of Use · Assigned to Intra Cellular Therapies Inc · Expires 2029-05-27 · 3y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent discloses methods and compositions for treating disorders involving the 5-HT2A, SERT, and/or dopamine D2 pathways.

USPTO Abstract

Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3271 — lumateperone-tosylate
U-3271 — lumateperone-tosylate
U-3271 — lumateperone-tosylate

Patent Metadata

Patent number
US10117867
Jurisdiction
US
Classification
Method of Use
Expires
2029-05-27
Drug substance claim
No
Drug product claim
No
Assignee
Intra Cellular Therapies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.